Patents Assigned to Sanof Aventis
  • Anti-CD38 antibodies for the treatment of cancer
    Patent number: 8153765
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: April 10, 2012
    Assignee: Sanof Aventis
    Inventors: Peter U. Park, Laura M. Bartle, Anna Skaletskaya, Viktor Golmakher, Daniel Tavares, Jutta Deckert, Vincent Mikol, Veronique Blanc
  • Furosemide modulators of HM74
    Patent number: 7556931
    Abstract: Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: July 7, 2009
    Assignees: Aventis Pharmaceuticals Inc., sanof-aventis Deutschland GmbH
    Inventors: Ann Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Hans-Jochen Lang